Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Marathon Petroleum Corp (MPC) Price & Performance

Heron Therapeutics IncTrade
Marathon Petroleum CorpTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Marathon Petroleum Corp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Marathon Petroleum Corp trades at $461.46 (market cap $130.12B). The key difference: Marathon Petroleum Corp is far larger — about 1913.2× Heron Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Marathon Petroleum Corp for 54 Days on average.

HRTXMPC
Market Cap
$68.01M$130.12B
Volume
1,891,9412,749,647
Sector
HealthEnergy
52-Week High
$1.49$463.34
52-Week Low
$0.27$162.63
Typical Hold Time
35 Days54 Days
Enterprise Value
$174.75M$156.64B
Dividend Yield
—0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.

While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.

Marathon Petroleum Corp

Marathon Petroleum (MPC) trades at $442.26, up 2.29% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 15.33, ROE of 47.9%, and consistent earnings beats in recent quarters. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions pose headwinds. Technical indicators show the stock trading near pivot point resistance at $442 with RSI suggesting potential overbought conditions.

MPC presents a compelling value opportunity with attractive valuation metrics and strong profitability, though investors face risks from potential regulatory changes and volatile energy markets. Analyst consensus remains strongly bullish with 76% buy ratings and a $420.30 price target, suggesting modest downside from current levels. The company's solid cash flow generation and dividend payments provide shareholder returns support.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HRTX
8% Buy92% Sell
Avg holding period · 35 Days
MPC
49% Buy51% Sell
Avg holding period · 54 Days

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX →

About Marathon Petroleum Corp

Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.

Read more on MPC →